Overview
Asimov provides synthetic biology platforms like CHO Edge for high-titer, stable CHO cell line development to accelerate therapeutic production. The company offers GMP-qualified HEK293 suspension cell lines for viral vector manufacturing in cell and gene therapies. Additional tools include AAV Edge, a suite of AI models, host cells, and genetic constructs for end-to-end gene therapy development.
Frequently asked questions
- What cell line development platforms does Asimov offer?
- Asimov offers CHO Edge for generating high-titer, stable CHO cell lines optimized for molecule-specific expression, and AAV Edge for gene therapy production including AI models, host cells, and genetic tools.
- Does Asimov provide GMP-compliant solutions?
- Yes, Asimov's clonal HEK293 suspension cell line is GMP-banked and qualified for viral vector production in preclinical and clinical manufacturing.
- What are Asimov's key partnerships in manufacturing?
- Asimov partners with CDMOs like Lotte Biologics for scaling CHO Edge to GMP manufacturing, Center for Breakthrough Medicines for HEK293 viral vectors, and others like Ottimo Pharma and RevOpsis for cell line development.